X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DIVIS LABORATORIES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DIVIS LABORATORIES NOVARTIS/
DIVIS LABORATORIES
 
P/E (TTM) x 360.4 38.2 942.8% View Chart
P/BV x 40.0 6.2 644.6% View Chart
Dividend Yield % 1.1 0.7 158.1%  

Financials

 NOVARTIS   DIVIS LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-18
DIVIS LABORATORIES
Mar-18
NOVARTIS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs7581,142 66.4%   
Low Rs579533 108.6%   
Sales per share (Unadj.) Rs228.4146.6 155.8%  
Earnings per share (Unadj.) Rs31.733.0 96.1%  
Cash flow per share (Unadj.) Rs32.838.4 85.3%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.51.2 125.3%  
Book value per share (Unadj.) Rs297.1222.8 133.3%  
Shares outstanding (eoy) m24.69265.47 9.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.95.7 51.2%   
Avg P/E ratio x21.125.3 83.1%  
P/CF ratio (eoy) x20.421.8 93.6%  
Price / Book Value ratio x2.23.8 59.9%  
Dividend payout %31.530.3 104.1%   
Avg Mkt Cap Rs m16,505222,318 7.4%   
No. of employees `0000.710.8 6.2%   
Total wages/salary Rs m1,4454,561 31.7%   
Avg. sales/employee Rs Th8,441.33,616.0 233.4%   
Avg. wages/employee Rs Th2,163.6423.8 510.6%   
Avg. net profit/employee Rs Th1,173.1814.9 143.9%   
INCOME DATA
Net Sales Rs m5,63938,915 14.5%  
Other income Rs m1,7181,134 151.5%   
Total revenues Rs m7,35740,049 18.4%   
Gross profit Rs m-6312,617 -0.5%  
Depreciation Rs m251,425 1.8%   
Interest Rs m5513 415.8%   
Profit before tax Rs m1,57512,313 12.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7923,543 22.3%   
Profit after tax Rs m7848,770 8.9%  
Gross profit margin %-1.132.4 -3.4%  
Effective tax rate %50.328.8 174.6%   
Net profit margin %13.922.5 61.7%  
BALANCE SHEET DATA
Current assets Rs m9,52245,351 21.0%   
Current liabilities Rs m3,2966,507 50.7%   
Net working cap to sales %110.499.8 110.6%  
Current ratio x2.97.0 41.4%  
Inventory Days Days37127 28.9%  
Debtors Days Days2895 29.9%  
Net fixed assets Rs m4621,160 0.2%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m7,21358,625 12.3%   
Net worth Rs m7,33659,156 12.4%   
Long term debt Rs m00-   
Total assets Rs m11,10567,832 16.4%  
Interest coverage x29.5926.8 3.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.6 88.5%   
Return on assets %7.612.9 58.3%  
Return on equity %10.714.8 72.0%  
Return on capital %22.220.8 106.7%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m6132,359 0.2%   
Fx outflow Rs m3,6309,042 40.1%   
Net fx Rs m-3,57023,317 -15.3%   
CASH FLOW
From Operations Rs m1,6107,759 20.7%  
From Investments Rs m687-4,783 -14.4%  
From Financial Activity Rs m-2,677-3,142 85.2%  
Net Cashflow Rs m-380-166 228.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.8 16.9%  
FIIs % 1.6 19.0 8.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.2 125.0%  
Shareholders   41,647 31,796 131.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 18, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - TORRENT PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS